{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:40:02Z","timestamp":1790840402572,"version":"4.1.0"},"reference-count":56,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.2217\/fon-2022-1237","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T15:20:59Z","timestamp":1682090459000},"page":"631-642","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":41,"title":["STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7017-8160","authenticated-orcid":false,"given":"Amer M","family":"Zeidan","sequence":"first","affiliation":[{"name":"Yale University & Yale Cancer Center,\rNew Haven,\rCT 06510,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristoteles","family":"Giagounidis","sequence":"additional","affiliation":[{"name":"Marien Hospital D\u00fcsseldorf,\rD\u00fcsseldorf,\r40479,\rGermany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkael A","family":"Sekeres","sequence":"additional","affiliation":[{"name":"Division of Hematology, Sylvester Cancer Center, University of Miami,\rMiami, FL\r33065,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Xiao","sequence":"additional","affiliation":[{"name":"Blood Diseases Hospital, Chinese Academy of Medical Sciences,\rTianjin,\r300020,\rChina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo F","family":"Sanz","sequence":"additional","affiliation":[{"name":"Hospital Universitario y Polit\u00e9cnico La Fe,\rValencia,\r46026,\rSpain"},{"name":"Health Research Institute La Fe (IIS La Fe),\rValencia,\r46026,\rSpain"},{"name":"CIBERONC, Instituto de Salud Carlos III,\rMadrid,\r28029,\rSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies Van","family":"Hoef","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG,\rBasel,\r4056,\rSwitzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ma","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation,\rEast Hanover,\rNJ07936,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Hertle","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG,\rBasel,\r4056,\rSwitzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Santini","sequence":"additional","affiliation":[{"name":"MDS Unit, Hematology, University of Florence,\rFlorence,\r50121,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-015-0269-y"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu180"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000150"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.04.001"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2021.1875600"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25247"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.8135"},{"key":"e_1_3_6_12_1","unstructured":"National Comprehensive Cancer Network . National Comprehensive Cancer Network: Myelodysplastic Syndromes (Version 1.2022) (2021). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mds.pdf"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-700054"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1464155"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.878934"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1953"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25488"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2019.01.002"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S39536"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.186"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30903"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.220"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0070-8"},{"key":"e_1_3_6_25_1","volume-title":"American Society of Hematology Virtual Congress.","author":"Garcia JS","year":"2020","unstructured":"Garcia JS , WeiAH, BorateUet al. Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase 1b study. Presented at: American Society of Hematology Virtual Congress.5\u20138 December 2020 (Abstract 656)."},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1697812"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-3-176"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000911"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltac019"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0224-6"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21492"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0180-3"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000846032.37876.c9"},{"key":"e_1_3_6_34_1","volume-title":"2022 American Society of Hematology (ASH) Annual Meeting and Exposition.","author":"Zeidan AM","year":"2022","unstructured":"Zeidan AM , AndoK, RauzyOet al. Primary Results of STIMULUS-MDS1: a randomized, double-blind, placebo-controlled phase II study of TIM-3 inhibition with sabatolimab added to hypomethylating agents (HMAs) in adult patients with higher-risk myelodysplastic syndromes (MDS) [oral]. Presented at: 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.New Orleans, LA, USA12 December 2022 (Abstract 853)."},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16074"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2014.89"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2015.07.011"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10738"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4746"},{"key":"e_1_3_6_40_1","volume-title":"2021 American Society of Hematology (ASH) Annual Meeting and Exposition.","author":"Brunner AM","year":"2021","unstructured":"Brunner AM , EsteveJ, PorkkaKet al. Efficacy and safety of sabatolimab in combination with hypomethylating agents in patients with very high\/high-risk myelodysplastic syndrome and acute myeloid leukemia: final analysis from a phase Ib study. Presented at: 2021 American Society of Hematology (ASH) Annual Meeting and Exposition.Atlanta, GA, USA, 10\u201314 December 2021."},{"key":"e_1_3_6_41_1","volume-title":"2020 American Society of Hematology Virtual Congress.","author":"Wei AH","year":"2020","unstructured":"Wei AH , EsteveJ, PorkkaKet al. Sabatolimab (MBG453) dose selection and dose-response analysis in myelodysplastic syndrome\/acute myeloid leukemia: population pharmacokinetics modeling and evaluation of clinical efficacy\/safety by dose.. Presented at: 2020 American Society of Hematology Virtual Congress.5\u20138 December 2020."},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(96)00274-6"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0367-7"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1210"},{"key":"e_1_3_6_47_1","volume-title":"European Hematology Association Virtual Congress.","author":"Wei A","year":"2021","unstructured":"Wei A , GarciaJ, BorateUet al. Updated safety and efficacy of venetoclax in combination with azacitidine for the treatment of patients with treatment-naive higher-risk myelodysplastic syndromes: phase Ib results. Presented at: European Hematology Association Virtual Congress.9\u201317 June 2021 (Abstract EP917)."},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1349100"},{"key":"e_1_3_6_49_1","volume-title":"European Hematology Association Virtual Congress.","author":"Sallman D","year":"2020","unstructured":"Sallman D , MalkiMA, AschAet al. The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in MDS patients: phase 1b results. Presented at: European Hematology Association Virtual Congress.11\u201314 June 2020 (Abstract S187)."},{"key":"e_1_3_6_50_1","volume-title":"European Hematology Association Annual Congress.","author":"Sallman DA","year":"2022","unstructured":"Sallman DA , AlMalki MM, AschASet al. Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1B study results. Presented at: European Hematology Association Annual Congress.Vienna, Austria, 9\u201312 June 2022 (Abstract S166)."},{"key":"e_1_3_6_51_1","unstructured":"Gilead Sciences Inc . Gilead Sciences Inc: FDA lifts partial clinical hold on MDS and AML magrolimab studies (2022). https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2022\/4\/fda-lifts-partial-clinical-hold-on-mds-and-aml-magrolimab-studies"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000843408.31385.3f"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-785915"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007334"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200008"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-1237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:47:00Z","timestamp":1719125220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-1237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.2217\/fon-2022-1237"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-1237","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}